Back to News
Market Impact: 0.3

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

ABSIALBONDAQSPY
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsAnalyst EstimatesAnalyst InsightsHealthcare & Biotech
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) reported a quarterly loss of $0.32 per share, in line with Zacks consensus and an improvement from $0.80 a year prior, though the company has consistently missed EPS estimates over the last four quarters. ABSI shares have significantly underperformed, down 48.8% year-to-date against the S&P 500's -11.7%. The stock's future trajectory hinges on management's earnings call commentary and estimate revisions, with its current Zacks Rank #3 (Hold) suggesting in-line market performance despite a favorable industry outlook.

Analysis

Absci Corporation (ABSI) reported a quarterly loss of $0.32 per share, meeting the Zacks Consensus Estimate and representing a notable improvement from the $0.80 loss per share recorded in the same quarter a year ago. However, this in-line result is set against a backdrop of consistent underperformance, as the company has failed to surpass consensus EPS estimates over the last four quarters, including a -13.79% negative surprise in the prior period. This operational uncertainty is reflected in the stock's severe market underperformance, having declined 48.8% year-to-date compared to the S&P 500's 11.7% loss. The forward-looking picture remains cautious; with a Zacks Rank #3 (Hold), the stock is expected to perform in line with the market. While the company operates within a favorably ranked industry (top 33% of Zacks industries), its future trajectory is heavily dependent on management's qualitative guidance from the earnings call and subsequent analyst estimate revisions for the upcoming quarters, which are currently projected at a loss of $0.32 per share on $1.67 million in revenue.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo